Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

Published 2016 View Full Article

Authors

Keywords

Journal

CANCER RESEARCH

Volume 76, Issue 4 Supplement, Pages S5-07-S5-07

Publisher

American Association for Cancer Research (AACR)

Online

2016-05-20

DOI

10.1158/1538-7445.sabcs15-s5-07

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CANCER RESEARCH

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.